NEW YORK (360Dx) – Bruker announced this week that it has completed its previously announced acquisition of an 80 percent majority interest in Nehren, Germany-based Hain Lifescience. Hain is a provider of molecular diagnostics for the detection of microbial and viral pathogens, as well as for molecular antibiotic resistance testing.  Bruker has options to acquire the remaining 20 percent equity interest held by the Hain founders, exercisable in or after 2022.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.